Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
| ▸ | FAAH | O00519 | 8/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 5/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5065679 | 1.00 | GHSR (0.46) | GHSRFAAHCA12CA1CA2 | |
| SCHEMBL772183 | 0.98 | GHSR (0.46) | GHSRFAAHCA12CA1CA2 | |
| SCHEMBL3071576 | 0.86 | FAAH (0.51) | GHSRFAAHTRPV1CYP3A4ALDH1A1 | |
| SCHEMBL3071572 | 0.86 | FAAH (0.51) | GHSRFAAHTRPV1CYP3A4ALDH1A1 | |
| SCHEMBL3775772 | 0.84 | FAAH (0.48) | GHSRFAAHTRPV1CYP3A4ALDH1A1 | |
| SCHEMBL3775768 | 0.84 | FAAH (0.48) | GHSRFAAHTRPV1CYP3A4ALDH1A1 | |
| SCHEMBL12377198 | 0.84 | CA12 (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7748042 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL7748046 | 0.83 | CA12 (0.57) | CA12CA1CA2CA7CA9 | |
| SCHEMBL16512867 | 0.81 | CA12 (0.50) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7973026-B2 | Thienopyrroles as antiviral agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2011-07-05 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | GENELABS TECHNOLOGIES, INC. | 2008-10-09 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304085-B2 | Nitrogen-containing heteroaryl derivatives | GENELABS TECHNOLOGIES, INC. (US) | 2007-12-04 | — | — | US | disclosed |
| EP-1631554-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2006-03-08 | — | — | EP | disclosed |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | SMITHKLINE BEECHAM CORPORATION | 2005-07-14 | — | — | US | disclosed |
| WO-2004108687-A2 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES FOR THE TREATMENT OF HCV-INFECTION | GENELABS TECHNOLOGIES, INC. (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247992-A1 | NITROGEN-CONTAINING HETEROARYL DERIVATIVES | EIF2AK2, MAVS, NSUN3 | GHSR 4667/4885FAAH 2166/4885CA12 4343/4885 |
| US-20050154040-A1 | Nitrogen-containing heteroaryl derivatives | EIF2AK2, MAVS, NSUN3 | GHSR 4667/4885FAAH 2166/4885CA12 4343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.